Female patients receiving ribavirin and the partners of male patients receiving
ribavirin must avoid pregnancy, using at least two reliable forms of contraception, during
treatment and for 6 months after completion of treatment. To monitor maternal-fetal outcomes of pregnant women or female partners of male patients exposed to ribavirin, a Ribavirin Pregnancy Registry has been established. Healthcare providers are encouraged to register patients by calling 1-800-593-2214 (USA).